IAA - Intranasal insulin and Abatacept trial
For the first time in Australia, researchers will carry out a type 1 diabetes trial to test two different immune therapies in children and young adults who have been recently diagnosed with type 1 diabetes. The IAA trial is now recruiting participants in Melbourne, Perth, Adelaide, Brisbane and Sydney.
What does ATIC do?
ATIC is working across six distinct interconnected Domains to ensure maximum impact and fulfil our bold vision.
Clinical trials
Drive the implementation of immunotherapy clinical trials throughout Australia and New Zealand
Community engagement
Work closely with the type 1 diabetes community across the research cycle, from trial development through recruitment to communication of...
Data management
Harmonise data collection and ensure linkage with national and international diabetes networks.
Education and training
Train, equip and update clinicians, scientists and the wider community on the fundamentals of immunotherapy, as well as the latest...
Preclinical and translation
Attract immunotherapy trials to Australasia through innovation: the discovery of improved biomarkers, development of new therapies, and facilitation of biosample...
Regulation and government
Advocate for regulatory approval and government funding of immunotherapy treatments for type 1 diabetes.
Beyond Insulin - September seminar
The next seminar in our Beyond Insulin series will take place Thursday the 21st of September from 1pm – 2pm. Associate Professor Stuart Mannering will present ‘Who killed my beta cells and why did they do it?’. Join us live for the seminar and Q&A.
T1D RELAY – New clinical trial now open
September 2023
ATIC and The Royal Melbourne Hospital are now seeking people aged 8-45 years with recently diagnosed type 1 diabetes (within three months) for a new clinical trial of two disease-modifying medications rituximab-pvvr and abatacept, called T1D RELAY.
Who killed my beta cells and why did they do it?
September 2023
Seminar 10 of the Beyond Insulin Seminar Series features Associate Professor Stuart Mannering who will discuss one of the fundamental outstanding questions in the immunology of T1D – how and why does the immune system attack the insulin producing cells?
Role of the gut microbiota in T1D
July 2023
Seminar 9 of the Beyond Insulin Seminar Series features Associate Professor Emma Hamilton-Williams. A/Prof Hamilton-Williams will discuss results from a clinical trial that aimed to restore a ‘healthy’ gut microbiota in adults with type 1 diabetes.
All trial sites for the Nasal Insulin and Abatacept (IAA Trial) are now open
June 2023
For the first time in Australia, researchers will carry out a type 1 diabetes trial to test two different immune therapies in children and young adults who have been recently diagnosed with type 1 diabetes.
We partner with global leaders in our field
Supported by
Coordinating Centre
